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Abstract
Methamphetamine (METH), an addictive psycho-stimulant drug exerts euphoric effects on users and abusers. It is also
known to cause cognitive impairment and neurotoxicity. Here, we hypothesized that METH exposure impairs the glucose
uptake and metabolism in human neurons and astrocytes. Deprivation of glucose is expected to cause neurotoxicity and
neuronal degeneration due to depletion of energy. We found that METH exposure inhibited the glucose uptake by neurons
and astrocytes, in which neurons were more sensitive to METH than astrocytes in primary culture. Adaptability of these cells
to fatty acid oxidation as an alternative source of energy during glucose limitation appeared to regulate this differential
sensitivity. Decrease in neuronal glucose uptake by METH was associated with reduction of glucose transporter protein-3
(GLUT3). Surprisingly, METH exposure showed biphasic effects on astrocytic glucose uptake, in which 20 mM increased the
uptake while 200 mM inhibited glucose uptake. Dual effects of METH on glucose uptake were paralleled to changes in the
expression of astrocytic glucose transporter protein-1 (GLUT1). The adaptive nature of astrocyte to mitochondrial b-
oxidation of fatty acid appeared to contribute the survival of astrocytes during METH-induced glucose deprivation. This
differential adaptive nature of neurons and astrocytes also governed the differential sensitivity to the toxicity of METH in
these brain cells. The effect of acetyl-L-carnitine for enhanced production of ATP from fatty oxidation in glucose-free culture
condition validated the adaptive nature of neurons and astrocytes. These findings suggest that deprivation of glucose-
derived energy may contribute to neurotoxicity of METH abusers.
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Introduction
Methamphetamine (METH) is the second most popular illicit
drug widely used in the world. It is very prevalent in Western,
Southern and Midwestern states of USA [1]. The escalating
problems due to METH abuse in these states cost enormous
financial and health burdens to family and society. The adverse
effects of METHabuse include addiction,impairment of behavioral
and cognitive function, and neurotoxicity [2,3,4,5]. METH abuse is
known to promote neurotoxicity by altering dopamine levels [6], as
such initial accumulation and long-term depletion of dopamine in
the brain causing loss of dopaminergic neurons [7,8]. Acute high
doses of METH lead to hyperthermia and neurotoxicity with
dopamine depletion, while chronic METH abuse seems to cause
hypothermia without depletion of dopamine [9]. Interestingly,
accumulation of dopamine in chronic self-administration of METH
triggers the activation of microglia and loss of neurons in human
brain [10,11]. Exacerbated dopaminergic neuronal death was also
demonstrated by dopamine overloading [12]. Initial dopamine
accumulation and gradual long-term dopamine depletion associat-
ing with neurotoxicity is a typical mechanism of action of METH
abuse [13,14]. This is because the ability of METH to release
dopamine rapidly and inhibits the reuptake, and/or perhaps
blocking the metabolism of dopamine in the reward regions
produces the euphoric feeling to METH abusers.
The induction of oxidative stress in dopaminergic neurons also
supports the role of dopamine in METH mediated neurotoxicity
[15]. Recently, Ramirez et al. (2009) and Sharma et al. (2010)
demonstrated the METH-elicited disruption of BBB and neuro-
toxicity as a result of oxidative stress [16,17]. These reports are in
line with the findings that antioxidants attenuate METH-induced
neuronal degeneration [18]. Interestingly, METH-induced neu-
ronal degeneration is often associated with the activation of
astroglial cells (astrocyte and microglia) in the brain [19,20]. One
common beneficial mediator for the survival of these cells is
governed by glucose uptake and metabolism. Therefore, impair-
ment of this glucose regulation by METH is expected to be
detrimental to the survival of these neuro-glial cells (neuron,
astrocyte and microglia). METH appeared to disrupt the
metabolism of glucose in the frontal cortex [21], thalamus and
striatum [22], and limbic areas of the brain [23].
To date there is no record of studies that demonstrate the effects
of METH on glucose uptake and glucose transporter in primary
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METH exposure may interfere with astrocytic glucose transporter
protein-1 (GLUT1) and neuronal GLUT3 function. GLUT1 and
GLUT3 are the principal glucose transporters that facilitate the
transport of glucose in the brain [24,25]. GLUT1 exists as 55 kDa
and 45 kDa isoforms, of which the highly glycosylated 55 kDa
GLUT1 isoform is localized exclusively in brain endothelial cells
[26,27]. The less glycosylated 45 kDa GLUT1 isoform is expressed
in the perivascular end-feet of astrocytes [28] and the 45-60 kDa
GLUT3 is localized exclusively in neurons [25]. Our findings
revealed that human neuronal GLUT3 and astrocytic GLUT1 are
affected by METH exposure. The use of GLUT inhibitor
cytochalasin B validated the importance of glucose uptake and
metabolism for the survival of these brain cells.
Materials and Methods
Reagents
Antibodies to GLUT1, GLUT3, glial fibrillary acidic protein
(GFAP, astrocytes marker) and neurofilament (NF, neuronal
marker) were purchased from Abcam (Cambridge, MA). Antibody
to a-actin was from Millipore (Billerica, MA). All secondary Alexa
Fluor antibodies were purchased from Invitrogen. D-(2-
3H)-
glucose (5 mCi, 185 MBq) was purchased from PerkinElmer Life
and Analytical Sciences (Waltham, MA). Cytochalasin B, acetyl-L-
carnitine (ALC, cofactor of b-oxidation) and 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) were pur-
chased from Sigma-Aldrich (St. Louis, MO).
Cell culture
Cortical neurons and astrocytes were obtained from our neural
tissue core facility. We routinely isolate these cells from elective
abortus specimens of human fetal brain tissues in our core facility.
Tissues were obtained in full compliance with the ethical
guidelines of both the National Institutes of Health (NIH) and
the University of Nebraska. Briefly, dissociated tissues were
incubated with 0.25% trypsin for 30 min, neutralized with 10%
fetal bovine serum, and further dissociated by trituration. Neurons
were cultured on poly-D-lysine pre-coated cover slips and 6 well
plates (BD Labware, Bedford, MA) in Neurobasal
TM Medium
containing 0.5 mM glutamine, 50 mg/ml each of penicillin and
streptomycin in combination with GIBCO
TMB-27 supplements
with antioxidants as described previously [29]. Astrocytes were
cultured in DMEM/F-12 media containing HEPES (10 mM),
sodium bicarbonate (13 mM, pH 7), 10% fetal bovine serum,
penicillin and streptomycin (100 mg/ml each, invitrogen) as
described [30]. Purity of neurons was assessed by MAP-2 antibody
(Chemicon) and astrocytes by GFAP antibody, which normally
showed 100% enrichment of neurons or astrocytes. For glucose
uptake and cell viability assays, cells were cultured in 96-well plates
(20,000 cells/well). Cells were plated on 12-well plates containing
glass cover slips (40,000 cells/well) for immunocytochemistry. For
protein extractions, astrocytes were cultured in T 75 cm
2 flasks
(1610
6 cells/flask) and neurons were cultured in 6 well plates
(0.2610
6 cells/well). Cell culture media was changed every 3rd
day until cells were confluent (4–5 days for astrocytes and 10–12
days for neurons).
Cell viability assay
Cell viability was determined by 3-(4,5-dimethylthiazol-2yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay. The assay is based on
the cleavage of yellow tetrazolium salt to purple formazan crystals
by metabolically active cells. Briefly, cells cultured in 96-well
microtiter plates were added 100 ml MTT (5 mg/ml MTT in 10%
FBS in 1X PBS) after treatments with test compounds for
appropriate time points. Cells were then incubated at 37uC for 45
minutes. Then 100 ml DMSO was added just after aspirating the
MTT solution and the plates were incubated at room temperature
for 15 min. Absorbance of the purple formazan was detected by a
microtiter plate reader at 490 nm wavelength.
Glucose uptake assay
Following the modified method of Takakura [31], D-(2-
3H)-
glucose uptake was performed on fully confluent human astrocytes
and neurons cultured in 96 well plates. Cells were exposed to
20 mM and 200 mM METH (for astrocytes) and 20 mM and
100 mM METH (for neurons) for 24 hr in the presence or absence
of 10 mM cytochalasin B (10 mM stock dissolved in DMSO) or
100 mM ALC. Cells were then incubated overnight in glucose-free
DMEM/F-12 media (for astrocytes) and glucose-free neurobasal
media (for neurons) containing equimolar of D-(2-
3H)-glucose
(1.0 mCi) and non-radiolabeled glucose. After washing off the
excess
3H-glucose with Krebs-Ringer phosphate-HEPES (KRPH)
buffer, cellular protein was precipitated with 10% TCA at 4uC for
15 min. Precipitated proteins were transferred onto a 96 well
nitrocellulose filter using the Unifilter-96 well Harvester as per the
manufacturer’s instructions (PerkinElmer, Waltham, MA). Using a
Beckman 96 well plate reader, radioactivity was measured by b-
top counter.
Immunocytochemistry
For immunocytochemistry, primary human astrocytes and
neurons were cultured on glass cover slips in 12 well plates until
80–100% confluent. Cells were then treated with 20 mM (for
neuron and astrocytes) and 200 mM of METH for astrocytes or
100 mM of METH for neurons in the presence or absence of
cytochalasin B (10 mM) or ALC (100 mM) for 24 hours. Cells were
washed with PBS and fixed in ice-cold acetone-methanol (1:1 v/v).
After blocking the cellular antigen with 3% bovine serum albumin
at room temperature for 1 hr in the presence of 0.1% Triton X-
100, cells were incubated overnight at 4uC with respective primary
antibodies: mouse anti-GLUT1 (1:250 dilution) and rabbit anti-
GFAP (1:200 dilution) for astrocytes; rabbit anti-GLUT3 (1:250
dilution) and mouse anti-NF (1:250 dilution) for neurons. Cells
were washed and then incubated for 1 hr with secondary
antibodies; anti-mouse-IgG Alexa Fluor 594 for GLUT1, anti-
rabbit-IgG Alexa Fluor 488 for GFAP, anti-rabbit-IgG Alexa
Fluor 594 for GLUT3 and anti-mouse-IgG Alexa Fluor 488 for
NF. Cover slips were then mounted onto glass slides with
immunomount containing DAPI (Invitrogen), and then fluores-
cence microphotographs were captured by fluorescent microscopy
(Eclipse TE2000-U, Nikon microscope, Melville, NY) using NIS-
Elements (Nikon, Melville, NY) software.
Western blotting
Astrocytes cultured in T-75 cm
2 flasks and neurons cultured in
6 well plates were lysed with CellLytic-M (Sigma) for 30 min at
4uC, centrifuged at 14000 x g, and cell lysates protein
concentrations in the supernatants were estimated by BCA
(Thermo Scientific, Rockford, IL). We loaded 20 mg protein/lane
and resolved the proteins by SDS-PAGE on 4-15% gradient gels
(Thermo Scientific) and then transferred the protein onto
nitrocellulose membranes. After blocking with Superblock T-20
(Thermo Scientific, Rockford, IL) membranes were incubated for
overnight with primary antibody against GLUT1 for astrocytes
and GLUT3 for neurons (1:1000, Abcam, Cambridge, MA) at
4uC followed by 1 hr incubation with secondary antibodies
conjugated with horse-radish peroxidase. Immunoreactive bands
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Scientific) using an autoradiography developer. Data were
quantified as arbitrary densitometry intensity units by Gelpro32
software package (Version 3.1, Media Cybernetics, Marlow, UK).
ATP production assay
Using pyruvate (PVA, 4.0 mM) and palmitate (PA, 4.0 mM) as
substrates, the production of adenosine triphosphate (ATP) via
mitochondrial b-oxidation was determined by ATP determination
kit (Molecular Probes, Eugene, OR) in glucose-free neuronal and
astrocytic cell cultures as described by Drew and Leeuwenburgh
[32]. The standard curve was extrapolated from 0.125, 0.25, 0.5,
1.0, 2.0, 4.0, 8.0, and 16.0 mM concentrations of ATP. The
reaction mixture was maintained at 28uC, and the luciferase assay
for ATP production was performed on fluorescence plate reader
with luminometer function (M5, Molecular Devices, Sunnyvale,
CA) using 96 well plates. ATP levels were normalized to milligram
cellular protein derived from the protein estimation of the 96 well
plates by BCA method.
Statistical analysis
All result values are expressed as the mean 6 SEM. Within an
individual experiment, each data point was determined from three
to five replicates. Statistical analysis of the data was performed
using GraphPad Prism V5 (Sorrento Valley, CA). Comparisons
between samples were performed by one-way ANOVA with
Dunnett’s post-hoc test. Differences were considered significant at
P values #0.05.
Results
Neurotoxicity of METH and its effect in glucose utilization
We first determined the dose-dependent effects of METH (2 -
200 mM) on neuronal toxicity. Our data indicate that treatment of
neurons with METH concentrations of 2 - 100 mM for 24 hr had
no significant effect on cell viability, but the high concentration
(200 mM) of METH affected neuronal survival, which was
attributed to direct toxicity of METH (Fig. 1A). In order to
evaluate whether the long-term exposure of low METH
concentration (20 mM) can affect neuronal survival by inhibiting
glucose uptake, we analyzed the viability of neurons in the
presence or absence of GLUT inhibitor cytochalasin B at non-
toxic level of 10 mM. Concentration of cytochalasin B higher than
20 mM almost completely inhibited GLUT3 function in primary
human neuronal culture causing neurotoxicity (data not shown).
The non-toxic concentration of cytochalasin B (10 mM) was
derived from dose- and time-dependent toxicity assay using
cytochalasin B concentrations of 0.5–100 mM treatment for 24–
72 hrs (data not shown). Optimization of non-toxic concentration
was important because cytochalasin B has diverse effects on
cellular function including cell division, actin polymerization and
platelet aggregation [33]. Neurons cultured in 96 well plates were
treated for 72 hrs and analyzed for cell viability by MTT assay.
The results showed that although 20 mM METH and 10 mM
cytochalasin B individually affected cell survival, combination of
METH and cytochalasin B exacerbated the loss of cell viability
(Fig 1B). Since cytochalasin B exacerbated the effect of METH,
these data suggest that the impairment of glucose transporter
function may contribute to neuronal loss in chronic METH
exposure. The protective effect of ALC from METH and
cytochalasin B in part supported the notion that an alternative
energy utilization pathway or oxidative stress may be involved for
neuronal loss during intracellular glucose deprivation.
METH exposure inhibits GLUT3 and glucose uptake in
neurons
To evaluate whether METH exposure can disrupt glucose
uptake, we treated neuronal culture with 20 mM and 100 mMo f
METH for 24 hr. Cells were then used for glucose uptake assay
and extraction of protein for analysis of GLUT3 protein levels.
The uptake of glucose by neurons decreased gradually with
increasing METH concentrations dose-dependently (Fig 2A). We
tested the inhibitory (with cytochalasin B) and protective (with
ALC) effects on neuronal glucose uptake using low and high
concentrations of 20 mM and 100 mM of METH. As expected,
cytochalasin B inhibited the rate of glucose uptake in presence or
absence of METH, however ALC effectively protected neurons
from the adverse effect of 100 mM METH on glucose uptake
(Fig 2B). Note that the presence of cytochalasin B exacerbated the
inhibitory effects of METH on glucose uptake at both tested
concentrations, suggesting that interference of neuronal glucose
transport and metabolism by METH may contribute to neuronal
degeneration.
Figure 1. Effect of METH-induced glucose deprivation on
neuronal viability: A. Dose dependent effects of METH on cell
viability in human neurons at 24 hr. B. Cell viability assay of human
neurons treated with 20 mM METH in presence or absence of
cytochalasin B (10 mM) or ALC (100 mM) for 72 hr. Statistically significant
(n=5), **p,0.01 compared with controls in A and B;
#P,0.05 with
20 mM METH in B; and
@p,0.05 with 10 mM cytochalasin B in B.
doi:10.1371/journal.pone.0019258.g001
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METH exposure highly reduced the expression of GLUT3
protein in primary human neuronal cultures (Fig 3A–F). Our
results indicate that primary human neurons expressed only
GLUT3 (not GLUT1, data not shown), and expression of GLUT3
exclusively in neurons was reported by Simpson et al. 2008 [25].
We observed that GLUT3 was localized mostly in neuronal cell
body and not in neurofilaments (Fig 3A–F). We also validated the
effects of cytochalasin B, ALC and METH on GLUT3 protein
levels by Western blot analyses. Our data demonstrated a
significant diminution of 45 kDa GLUT3 protein levels by
100 mM METH exposure and protective effect by ALC compared
with the control (Fig 4A–B). Treatment of neurons with
cytochalasin B did not alter GLUT3 protein levels (Fig 4A–B),
suggesting that cytochalasin B inhibits glucose uptake by blocking
the active binding of GLUT3 in neurons, but not by reducing the
level of GLUT3 protein.
Effects of METH on survival of astrocytes
Next, we tested the dose-dependent effects of METH on
viability of primary human astrocytes in culture. METH
concentrations of 5–200 mM had no significant effect on cell
toxicity while 500 mM METH showed significant toxic effect to
astrocytes (about 50% cell death compared with control) following
24 hr exposure (Fig 5A). We also evaluated the survival of
astrocytes after long-term exposure of non-toxic METH concen-
tration (20 mM). The use of non-toxic level cytochalasin B (10 mM,
GLUT inhibitor) was to examine the possible role of glucose
mishandling as contributing factor for cellular death in chronic
METH exposure at physiologically detected level. For this reason,
astrocytes cultured in 96 well plates were treated with METH for
72 hrs and analyzed for cell viability by MTT assay. Although
there was a pattern of reduction, our results showed that 10 mM
cytochalasin B or 20 mM METH individual treatment had no
significant effect on cell viability unlike the combination of
cytochalasin B and METH (Fig 5B). These results suggest that
long-term exposure of low dose METH may disrupt glucose
regulation and survival of astrocytes.
Effects of METH on human astrocytic glucose uptake
To correlate the loss of astrocytes with inhibition of glucose
uptake by these cells, we studied the dose-dependent effects of 5 –
500 mM METH on glucose uptake after exposing for 24 hr in
culture media. Surprisingly, we found that 5 – 20 mM METH
increased glucose uptake dose-dependently and above 20 mM
METH (50–500 mM) decreased glucose uptake gradually (Fig 6A).
Since there was a marked differential effect between 20 mM and
200 mM of METH on astrocytic glucose uptake, we studied the
inhibitory effect of cytochalasin B (10 mM) and the protective effect
of ALC (100 mM) on glucose uptake with these two METH
concentrations. The ALC concentration of 100 mM was derived
from dose dependent study of 50–500 mM on cell viability (data
not shown). Interestingly, ALC stabilized the inhibitory effect of
200 mM METH on glucose uptake to control level, suggesting that
ALC may ameliorate the impairment of glucose uptake (Fig 6B).
As expected, cytochalasin B inhibited the effect of 20 mM and
exacerbated the effect of 200 mM METH on glucose uptake,
suggesting the direct involvement of GLUT1 in human astrocytes
(Fig 6B).
Effects of METH on astrocytic GLUT1 protein expression
We then confirmed the expression of GLUT1 by immunocy-
tochemistry. In agreement with glucose uptake data, low dose of
METH (20 mM) increased the expression of GLUT1 protein,
Figure 2. METH down regulates glucose uptake in human
neurons: A. Dose dependent effects of METH on D-(2-
3H)-glucose
uptake by human neurons for 24 hr. B. Effects of GLUT inhibitor
cytochalasin B (10 mM) and ALC (100 mM) on glucose uptake by neurons
following 20 mM and 100 mM of METH for 24 hr. C. Effect of 20 mM
METH on D-(2-
3H)-glucose uptake in human neurons at 24, 48 and 72 hr
exposure periods and compared with respective untreated control cells.
Statistically significant, *p,0.05, **p,0.01 compared with controls
(n=5 in A and B,n = 3i nC);
##p,0.01 with 100 mM of METH (in B,
n=5).
doi:10.1371/journal.pone.0019258.g002
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(Fig 7A–F). ALC almost completely prevented the down regulation
of GLUT1 protein expression by high dose METH (200 mM) in
astrocytes (Fig 7E–H). In agreement with these findings, Western
blot analyses validated the protective effect of ALC on GLUT1
protein content from 200 mM METH (Fig 8A–B). Unlike GLUT1
in brain microvessels that express 55 kDa isoform, we detected a
distinct 45 kDa isoform GLUT1 protein in astrocytes (Fig 8A). We
also noted that unlike the glucose uptake findings, cytochalasin B
neither decreased the GLUT1 protein level from low dose METH
nor exacerbated the effect of high dose METH on 45 kDa isoform
GLUT1 protein levels in astrocytes (Fig 8A-B).
Can neurons and astrocytes adapt to alternative energy
metabolic pathway during glucose deprivation?
We asked this question because blockade of glucose uptake by
cytochalasin B (see Fig 6B) did not significantly affect astrocytic cell
death (see Fig 5B), suggesting that astrocytes might have turned on
to alternative energy metabolic mechanism. Also, because ALC
was protective (ALC a key cofactor of b-oxidation), we tested the
idea that these brain cells may be utilizing non-carbohydrate
substrates as the source of ATP for survival during METH-
induced mishandling of glucose. Thus, we assayed the mitochon-
drial oxidation of pyruvic acid (PV) and palmitic acid (PA) in
neurons and astrocytic culture in glucose-free media for analyses of
cell survival rate and ATP production. Our results indicate that
reduction of neuronal and astrocytic viability in glucose depriva-
tion was abrogated by 100 mM METH, which was mitigated by
supplementation of pyruvate (dose-dependently) and palmitate at
lower concentration in these two cell types (Figs 9A and B). Since
15 mM of pyruvate was already a high physiological concentra-
tion, we did not test the effect of PV above this level. We tested the
effect of PA up to 2.0 mM and found that lower concentrations of
50–250 mM afforded better protection than the higher concen-
trations. PA concentration higher 2.0 mM was less soluble in
media containing 0.02% DMSO.
Production of ATP from PV/PA was assessed to support the
argument that survival of these cells in glucose deprivation was due
to oxidation of PV/PA. In agreement with cell viability data, we
found that both neurons and astrocytes were capable of oxidizing
PV and PA in the presence or absence of METH, in which ALC
significantly enhanced the levels of ATP (Fig 9C and D). However,
it was apparent that astrocytes were better adaptive than neurons
for oxidation of fatty acids as source of energy. These results
suggest that brain cells like astrocytes and neurons do utilize
alternative energy metabolic mechanism during METH-induced
impairment of glucose utilization. These results suggest that
METH appears to impair GLUT1 function and glycolysis without
affecting Krebs cycle step that converts PV or PA to ATP as bio-
energy.
Figure 3. Effects of METH on GLUT3 expression in human neurons: Immunocytochemistry of GLUT3 (red) merged with NF (green) and DAPI
(blue) in control (A–B), 20 mM METH (C–D), and 100 mM METH+100 mM ALC (E–F). Rabbit anti-GLUT3 and mouse anti-NF were used as primary
antibodies for overnight at 4uC. Anti-rabbit-IgG Alexa Fluor 594 for GLUT3 and anti-mouse-IgG Alexa Fluor 488 for NF were used as secondary
antibodies. Scale bar indicates 10 mm in all panels.
doi:10.1371/journal.pone.0019258.g003
Figure 4. Western blot analysis for GLUT3 expression in METH
treated human neurons. A-B: Effects of METH on GLUT3 (45 kDa)
protein levels in human neurons. Bar graph shows the results, which are
expressed as ratio of GLUT3 to that of a-actin bands, and presented as
the mean values (6 SEM; n=5). (Statistically significant, **p,0.01
compared with controls).
doi:10.1371/journal.pone.0019258.g004
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We demonstrate here for the first time that METH exposure
had deleterious effects on glucose uptake and glucose transporter
proteins in primary human neurons and astrocytes culture. Our
data suggest that deprivation of glucose and inability of brain cells
to process the glucose for bio-fuel production is an important key
contributing mechanisms for neuronal degeneration in METH
abusers. Further, therapeutic application of ALC could be
beneficial for improving the health of METH abusers.
Glucose is the main energy source for the brain, which is
transported from the circulation to the brain by BBB endothelial
GLUT1. GLUT1 then delivers glucose to astrocytes via the
astrocytic 45 kDa GLUT1 isoform and to neurons via the
neuronal GLUT3 protein. The glycolytic product of glucose such
as pyruvate is transported into the neurons by endothelial and
astrocytic monocarboxylate transporter1 (MCT1) and out of the
neurons by neuronal MCT2 [24]. Interference in any of this
shuttling process is expected to disrupt the regulation of glucose
metabolism and energy utilization in the brain.
Therefore, inhibition of glucose uptake by methamphetamine
(METH) that we observed in astrocytes and neurons indicate that
glucose deprivation may be one of the putative mechanisms for
neurotoxicity in METH abusers. The rationale for implicating
these findings to pathophysiologic neurotoxicity in METH abusers
evolved from the fact that these cells are primary human brain
cells. Unlike astrocytes, neurons were very sensitive to METH
exposure. One reason for the differential effects could be
attributed to fetal origin and the adaptive nature of these cell
types. Fetal neurons are very sensitive to exogenous stress agents,
whereas glial cells like astrocytes are better adaptive to
environmental stress. It remains open for further investigation
whether neurons and astrocytes derived from adult brain will be
less sensitive to METH insults. This adaptive nature may also
explain the dual effects of METH on astrocytic glucose uptake. In
that, the effect of 20 mM METH for increasing glucose uptake
appeared to be an acute adaptive response of immune cells like
astrocytes because we observed that chronic exposure of 20 mM
METH decreased the glucose uptake in astrocytes. The low
(20 mM) and high (200 mM) concentrations of METH that we used
here were similar to the levels of METH detected in blood samples
of recreational users [34,35] and in chronic METH abusers [36].
Figure 5. METH-induced glucose deprivation cause cell death
in human astrocytes: A. Dose dependent effects of METH on cell
viability in human at 24 hr. B. Cell viability assay of human astrocytes
treated with 20 mM METH in presence or absence of cytochalasin B
(10 mM) or ALC (100 mM) for 72 hr and compared with untreated cells.
Statistically significant (n=5), **p,0.01 compared with controls in A
and B and
#p,0.05 with 20 mM METH or 10 mM cytochalasin B in B.
doi:10.1371/journal.pone.0019258.g005
Figure 6. Dual effects of METH on glucose uptake in astrocytes:
A. Dose dependent effects of METH on D-(2-
3H)-glucose uptake by
human astrocytes for 24 hr. B. Effects of GLUT inhibitor cytochalasin B
(10 mM) and ALC (100 mM) on glucose uptake by astrocytes following
20 mM and 200 mM of METH for 24 hr treatment. Statistically significant
(n=5), *p,0.05, **p,0.01 compared with controls in A and B and
#P,0.05,
##p,0.01 with 200 mM METH in B (third bar).
doi:10.1371/journal.pone.0019258.g006
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to utilization of non-carbohydrate substrate as an alternative
energy source during glucose-deprived stress condition. Such was
the case here when glucose delivery was limited by METH
exposure, ALC protected neurons and astrocytes from the adverse
effects of METH, suggesting the activation of fatty acid oxidation.
ALC is the primary cofactor of mitochondria b-oxidation of fatty
acids for ATP production [37]. This could be the alterative
survival mechanism as to why blockade of glucose uptake by
cytochalasin B (see Fig 6B) did not significantly affect astrocytic cell
death observed in figure 5B. We demonstrated that astrocytes
showed more efficient adaptive oxidation of PV/PA than neurons
for ATP production during glucose-deprived stress condition. We
propose that METH targeted glucose transport function in
neurons and astrocytes without severely affecting Krebs cycle,
because oxidation of PV/PA was still active in these cells even
after METH exposure in glucose deprivation. These findings
suggest that pyruvate dehydrogenase that converts pyruvate to
acetyl-coenzyme A was not the primary target of METH
exposure.
Another interesting observation was that ALC prevented the
METH-induced decrease in glucose uptake by stabilizing the
GLUT1 and GLUT3 protein levels. This can be possible if
METH exposure interferes GLUTs glycosylation and ALC can
stabilize the glycosylation by donating acetyl group to glucos-
amine. Thus, acetylglucosamine can glycosylate GLUT1 or
GLUT3 even in the presence of METH. This is because glucose
uptake and transport is possible only when the GLUTs are
enzymatically glycosylated by acetylglucosamine. As expected,
cytochalasin B decreased the rate of glucose uptake without
affecting glucose transporter protein levels. These findings showed
that cytochalasin B inhibited glucose uptake and transport by
modulating the active binding sites of GLUTs and not by
degrading the actual GLUTs protein contents. However, METH
altered glucose uptake and GLUTs protein levels. It would be
interesting to know whether decrease in glucose uptake and
GLUT protein levels in these cell types were related to the
impairment of glucose metabolism in brain as indicated in METH
abusers [21].
Finally, the question is whether chronic METH abuse causes
hypoglycemia due to blockade of glucose transport across the
blood-brain barrier or causes hyperglycemia as a result of passive
diffusion through defective BBB? Similar to our recent findings in
animal model, Fujioka et al. (1997) reported that METH abuse
causes a hypoglycemia in human brain [38]. Thus, this deficient
glucose level compounded with the inability of brain cells to
handle the available glucose (as demonstrated here) may likely be a
possible underlying mechanism for neuronal degeneration in
METH abuse. Our data also suggest that brain cells (neurons in
particular) might still be deprived of glucose-derived energy even
in hyperglycemic brain because under METH exposure these cells
are unable to utilize glucose efficiently due to impairment of
uptake and transport mechanisms. This is because handling of
glucose for energy generation is accomplished by active process
Figure 7. Expression of GLUT1 in METH treated human
astrocytes: A-H: Immunocytochemistry of GLUT1 (red) merged with
GFAP (green) and DAPI (blue) in human astrocytes. The expression of
GLUT1 is shown in control (A–B), 20 mM METH (C–D), 200 mM METH
(E–F) and 200 mM METH+100 mM ALC (G–H). Mouse anti-GLUT1 and
rabbit anti-GFAP were used as primary antibodies for overnight at 4uC.
Anti-mouse-IgG Alexa Fluor 594 for GLUT1 and anti-rabbit-IgG Alexa
Fluor 488 for GFAP were used as the secondary antibodies. Scale bar
indicates 10 mm in all panels.
doi:10.1371/journal.pone.0019258.g007
Figure 8. Western blot analysis of GLUT1 in METH treated
human astrocytes: A: Effects of METH on 45 kDa GLUT1 protein
levels in human astrocytes. The effects of cytochalasin B and ALC on
GLUT1 expression also showed in the band pattern. B. Results are
expressed as ratio of GLUT1 to that of a-actin bands, and presented as
the mean values (6 SEM; n=5). (Statistically significant, *p,0.05
**p,0.01 compared with controls).
doi:10.1371/journal.pone.0019258.g008
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utilization is likely to contribute for neurodegeneration in hypo/
hyper-glycemic brain in METH abusers.
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